手足综合征在卡培他滨联合贝伐珠单抗治疗HER2阴性局部复发/转移性乳腺癌中的预测作用  

Predictive role of hand-foot syndrome in patients receiving capecitabine plus bevacizumab for HER2-negative locally recurrent/metastatic breast cancer

作　　者：刘金鹏[1] 贾奇[1] 罗璐[1] 江静[1] 魏丹[1] 魏辉[1] 

机构地区：[1]陕西中医药大学附属医院肿瘤四科,陕西咸阳712000

出　　处：《肿瘤》2017年第4期391-397,共7页Tumor

摘　　要：目的:观察卡培他滨(capecitabine,CAP)联合贝伐珠单抗(bevacizumab,BEV)治疗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阴性局部复发/转移性乳腺癌(locally recurrent/metastatic breast cancer,LR/mBC)时,手足综合征(hand-foot syndrome,HFS)的出现与患者预后的关系。方法:100例HER2阴性LR/mBC患者接受CAP-BEV一线治疗,根据患者是否出现HFS分为HFS组和非HFS组,分析HFS与患者病理特征间的关系,采用COX比例风险模型分析影响患者无进展生存期(progressionfree survival,PFS)和总生存期(overall survival,OS)的相关因素。结果:绝经状态和转移器官数目在HFS组和非HFS组之间的差异有统计学意义(P值均<0.05)。HFS组中位PFS(10.7个月)明显长于非HFS组(5.8个月,P=0.007),HFS组中位OS(22.8个月)明显长于非HFS组(14.9个月,P<0.001)。美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)活动状态(performance status,PS)评分、激素受体状态、首诊转移情况、转移部位、转移器官数目和HFS与PFS有关(P值均<0.05)。ECOG PS评分、激素受体状态、首诊转移情况、转移部位和HFS均是影响PFS的独立危险因素(P值均<0.05)。绝经状态、ECOG PS评分、激素受体状态、首诊转移情况、转移器官数目和HFS与OS有关(P值均<0.05)。绝经状态、激素受体状态、首诊转移情况和HFS均是影响OS的独立危险因素(P值均<0.05)。结论:CAP-BEV治疗HER2阴性LR/mBC患者时,出现HFS的患者预后优于非HFS患者,HFS可以作为该治疗的一项疗效预测指标。Objective： To observe the correlation between hand-foot syndrome （HFS） and prognosis of patients with human epidermal growth factor receptor 2 （HER2）- negative locally recurrent/metastatic breast cancer （LR/mBC） receiving chemotherapy with capecitabine （CAP） plus bevacizumab （BEV）.Methods： One hundred patients with HER2-negative LR/mBC receiving first-line CAP plus BEV were divided into HFS group and non-HFS group, then the relationship between HFS and clinicopathologic characteristics of patients with HER2-negative LR/mBC and the related factors influencing the progression-free survival （PFS） and overall survival （OS） were analyzed by COX proportional hazards model.Results： There were statistically significant differences in menopausal status and the number of metastatic organs between HFS group and non-HFS group （all P 〈 0.05）. The median PFS of the HFS group was significantly longer than that of the non-HFS group （10.7 months vs 5.8 months, P = 0.007）. The median survival time of the HFS group was also significantly longer than that of the non-HFS group （22.8 months vs 14.9 months, P 〈 0.001）. There was an association of Eastern Cooperative Oncology Group （ECOG） performance status （PS） score, hormone receptor status, metastasis at first diagnosis, metastatic organ site, the number of metastases and HFS with PFS （all P 〈 0.05）. ECOG PS score, hormone receptor status, metastasis at first diagnosis, metastatic organ site and HFS were independent risk factors for PFS （all P 〈 0.05）. There was an association of menopausal status, ECOG PS score, hormone receptor status, metastasis at first diagnosis, the number of metastatic organ and HFS with OS （all P 〈 0.05）. Menopausal status, hormone receptor status, metastasis at first diagnosis, and HFS were independent risk factors for OS （all P 〈 0.05）.Conclusion： HFS can be used as a predictor of therapeutic effect of HER2-negative LR/mBC patients receiving CAP-BEV. The patients with HFS ha

关 键 词：乳腺肿瘤 肿瘤转移 肿瘤治疗方案 手足综合征 预后 

分 类 号：R737.9[医药卫生—肿瘤]